TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study

The purpose of this study is to evaluate the efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) plus Cadonilimab (a PD-1/CTLA-4 bispecific antibody) in advanced hepatocellular carcinoma (BCLC-C Stage) accompanied by tumor thrombosis-associated portal hypertension.

Trial Details

NCT ID
NCT05882370
Phase
PHASE2
Sponsor
Fei Gao
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Cadonilimab
  • transjugular intrahepatic portosystemic shunt (TIPS)
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • The patient voluntarily joined the study and signed an informed consent form;
  • ≥18 and ≤ 75 years old, both male and female;
  • Clinically diagnosed or pathologically confirmed hepatocellular carcinoma, at least one measurable focus without local treatment (according to mREC…
  • Child-Pugh score ≤ 13 points;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →